Facilitating cells in tolerance induction for kidney transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 1, 2015, Pages 57-63

  Yolcu, Esma S ^a   Leventhal, Joseph R ^b   Ildstad, Suzanne T ^a,c  

^a University of Louisville School of Medicine   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NuLease Medical Solutions   (United States)

Author keywords

chimerism; donor specific tolerance; facilitating cell therapy (FCRx); living kidney transplant

Indexed keywords

CD8 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; CANCER RISK; CHRONIC GRAFT VERSUS HOST DISEASE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROCHIMERISM; NEOPLASM; NONMYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL MOBILIZATION; ANIMAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; IMMUNOLOGY;

ANIMALS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION;

EID: 84921437858     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000156     Document Type: Review

References (53)

1. Fricke S, Hilger N, Fricke C, et al. Prevention of graft-versus-host-disease with preserved graft-versus-leukemia-effect by ex vivo and in vivo modulation of CD4+ T-cells. Cell Mol Life Sci 2013; 71:2135-2148.
2. Munchel AT, Kasamon YL, Fuchs EJ. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, posttransplantation cyclophosphamide. Best Pract Res Clin Haematol 2011; 24:359-368.
3. Passweg J, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplantation 2014; 49:744-750.
4. Saba N, Flaig T. Bone marrow transplantation for nonmalignant diseases. J Hematother Stem Cell Res 2002; 11:377-387.
5. Khalifian S, Grahammer J, Lee WPA, Brandacher G. Stem cell-based tolerance induction in transplantation. J Stem Cell Res Ther 2013; S6.
6. Barriga F, Ramierz P, Wietstruck A, Rojas N. Hematopoietic stem cell transplantation: clinical use and perspectives. Biol Res 2012; 45:307-316.
7. Dey B, Sykes M, Spitzer T. Outcomes of recipients of both bone marrow and solid organ transplants. Rev Med 1998; 77:355-369.
8. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:124ra28; PMC3610325.
9. Ravindra K, Leventhal J, Song DD, Ildstad ST. Chimerism and tolerance in solid organ transplantation. Clin Cell Immunol 2012; S9:003.
10. Havenith S, Yong S, van Donselaar-van der Pant K. Everolimus-Treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-Treated patients. Transplantation 2013; 95:184-191.
11. Ciancio G, Sageshima J, Akpinar E, et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. Transplantation 2013; 96:800-806.
12. Fraile P, Vazquez L, Caballero D, et al. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant. Eur J Haematol 2013; 91:129-134.
13. Szabolcs P, Burlingham WJ, Thomson AW. Tolerance after solid organ and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18 (1 Suppl):S193-S200.
14. Morton M, Coupes B, Roberts S, et al. Epstein-Barr virus infection in adult renal transplant recipients. Am J Transplant 2014; 14:1619-1629.
15. Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2014; 99:1574-1581.
16. Hugle T, van Laar JM. Allogeneic stem cell transplantation for rheumatic autoimmune diseases. Med Rep 2010; 2:22.
17. Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014; 124:1168-1172.
18. Gu F, Molano I, Ruiz P, et al. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW) F1 mice. Clin Immunol 2012; 145:142-152.
19. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-Tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16:838-847.
20. Bernardo M, Ball L, Cometa A, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-Threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation 2011; 46:200-207.
21. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42-48.
22. Najar M, Rouas R, Raicevic G, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11:570-583.
23. Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24:1294-1301.
24. Moodley Y, Manuelpillai U, Weiss DJ. Cellular therapies for lung disease: a distant horizon. Respirology 2011; 16:223-237.
25. Wittwer T, Rahmanian P, Choi Y-H, et al. Mesenchymal stem cell pretreatment of nonheart-beating-donors in experimental lung transplantation. J Cardiothoracic Surg 2014; 9:151.
26. Lutz J, Thurmel K, Heemann U. Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm 2010; 7:27.
27. Feng B, Chen G, Zheng X, et al. Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury. Transplantation 2009; 87:1283-1289.
28. Raza K, Larsen T, Samaratunga N, et al. MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant. PLoS One 2014; 9:e109034.
29. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6:412-422.
30. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
31. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110:2764-2767.
32. Gonzalo-Daganzo R, Regidor C, Martin-Donaire T, et al. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy 2009; 11:278-288.
33. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
34. Xia G, He J, Zhang Z, Leventhal JR. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+CD25+ regulatory T cells. Transplantation 2006; 82:1749-1755.
35. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-Term survival of allografts. Am J Transplant 2008; 8:298-306.
36. Trzonkowski P, Bieniaszewska M, Juscinska J, et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127-T regulatory cells. Clin Immunol 2009; 133:22-26.
37. Brunstein CG, Miller JS, CaoQ, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117:1061-1070.
38. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
39. Kaufman CL, Colson YL, Wren SM, et al. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84:2436-2446.
40. Fugier-Vivier I, Rezzoug F, Huang Y, et al. Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med 2005; 201:373-383; PMCID: PMC2213023.
41. Schuchert MJ, Wright RD, Colson YL. Characterization of a newly discovered T-cell receptor beta-chain heterodimer expressed on a CD8+ bone marrow subpopulation that promotes allogeneic stem cell engraftment. Nat Med 2000; 6:904-909.
42. Rezzoug F, Huang Y, Tanner MK, et al. TNFa is critical to facilitation of hematopoietic stem cell engraftment and function. J Immunol 2008; 180: 49-57.
43. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 2013; 95:169-176; PMC3531567.
44. Leventhal JR, Elliott MJ, Yolcu ES, et al. Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants in press. Transplantation 2014.
45. Colson YL, Christopher K, Glickman J, et al. Absence of clinical GVHD and the in vivo induction of regulatory T cells after transplantation of facilitating cells. Blood 2004; 104:3829-3835.
46. Huang Y, Bozulic LD, Miller T, et al. CD8a+ plasmacytoid precursor DC induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood 2011; 117:2494-2505; PMC3062412.
47. Wen Y, Elliott MJ, Huang Y, et al. DOCK2 is critical for CD8+TCR-graft facilitating cells to enhance engraftment of hematopoietic stem and progenitor cells. Stem Cells 2014; 32:2732-2743.
48. Huang Y, Elliott MJ, Yolcu ES, et al. Two distinct, complementary and synergistic CD56 subpopulations that uniquely define human facilitating cell function (under review). Blood 2014.
49. Xu H, Ildstad ST. Transplantation: Is donor T-cell engraftment a biomarker for tolerance?. Nat Rev Nephrol 2012; 8:560-561.
50. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12:1133-1145.
51. Kawai T, Sachs D, Sprangers B, et al. Long-Term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014; 14:1599-1611.
52. Leventhal JR, Mathew JM, Salomon DR, et al. Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol 2013; 24:1376-1385.
53. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14:641-650.